Following the company’s announcement that its COVID-19 vaccine had a 66% overall efficacy rate, JNJ shares are down 3.56%. It was up nearly 18% in the last quarter. Meanwhile, vaccines currently being used, such as those from Pfizer (PFE) / BioNTech SE (BNTX) and Moderna (MRNA), offer an efficiency rate of nearly 95%.
Despite these reasons, analysts say such a fall in stocks seems unjustified. As a single-dose vaccine, the J&J vaccine is easier to administer to the general population than the Pfizer / Biontech or Moderna vaccines.
Besides, tests conducted among 43,783 individuals of different sexes, ages, and races have proven that vaccines are successful against new coronavirus strains, including one in the United States, Latin America, and South Africa. The new strains of diseases have not been tested yet by Pfizer / BioNTech or Moderna. Recent reports state that Pfizer and Novavax will test modified vaccines.
J&J vaccine, unlike that of Pfizer, doesn’t require ultra-low temperatures to be stored, and it can be transported in standard refrigerators. Combined with strong immunity lasting 28 days after vaccination and coronavirus cases being undetected 48 days after vaccination, the overall efficacy of 66% seems sufficient. However, the FDA stated that vaccines with a 50% effectiveness and safety rating would be permitted in the future. CDC data shows that the flu vaccine typically reduces a person’s chance of contracting the flu by between 40% and 60% compared to people who are not immunized.
J&J vaccine also provided significant protection against moderately severe COVID-19 infections in The U.S., Latin America, and South Africa, 72%, 66%, and 57%, respectively. The vaccine has also shown to be well tolerated without side effects. The vaccination caused a fever in 9% of people but no severe allergic reactions.
U.S. regulatory approval of the J&J vaccine is expected to take place in the next few weeks.
Janssen, a pharmaceutical subsidiary of Johnson & Johnson (JNJ), signed a contract with the Department of Health and Human Services last August to purchase 100 million doses of the vaccine for about $ 1 billion. Furthermore, the deal allows the federal government to order 200 million more doses.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Besides, Johnson & Johnson (JNJ) vaccine boasts the following factors which make it one of the most attractive vaccine choices for large government contracts: efficacy, safety, easy transport, and advantages of a single dose.